- Leveraging the effective launch of the Business’s RHO Phyto &#x 2122; branded sophisticated medical cannabis line of product in Canada, the portfolio of preparations, consisting of oil drops, sublingual sprays, pills and topicals, are now readily available across the country in Colombia through doctor prescription under the Magisterial design
- The medical program consists of Avicanna’s 3 pillars focused on setting the gold requirement for medical cannabis in Colombia and other Latin America n markets, consisting of M edical neighborhood education, A dvanced pharmaceutical— grade cannabinoid preparations and a C omprehensive client assistance program
- Accompanying the launch of the medical program, Avicanna is hosting its 2nd Colombian seminar Magisterial Solutions: Advances in Cannabinoid Research Study, Item Offering and Client Gain Access To
TORONTO, Dec. 10, 2020 (WORLD NEWSWIRE)– Avicanna Inc. (“ Avicanna” or the “ Business) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical business concentrated on the advancement, production and commercialization of plant-derived cannabinoid-based items reveals the launch of its medical cannabis program in Colombia, under substance drug store legislation “Formulaciones Magistrales”, in which Avicanna will supply its standardized, industry-leading cannabinoid formulary to clients and the medical neighborhood. Furthermore, this program consists of the education and training of the medical neighborhood and a detailed client assistance program.
Aras Azadian, CEO of Avicanna Inc., commented: “After 2 years of preparation, we are happy to be introducing this total program in a market that is really substantial to us and to be doing so with a medical neighborhood that we have actually been working carefully with for near to 3 years. Our company believe that this medical program will set the gold requirement for sophisticated cannabinoid-based medication in Colombia and will function as an evidence of idea for prepared growths into other Latin American markets.”
The pharmaceutical cannabinoid preparations, which need doctor prescription, will be advertised through a series of service designs consisting of direct sales to clients, shipment to nationwide drug stores and shipment to 3rd party medical organizations throughout Colombia. This extensive medical cannabis program is the very first of its kind in Colombia to be informing and training 3rd party healthcare professionals on the effectiveness of sophisticated cannabinoid-based medication throughout different medical indicators and comorbidities and offering suitable cannabinoid options. The target restorative locations consist of neurological conditions such as epilepsy, Parkinson’s illness, several sclerosis, psychiatric indicators such as PTSD, stress and anxiety, anxiety along with persistent discomfort.
This very first total portfolio of sophisticated cannabinoid preparations makes up the very same clinically established formulas as Avicanna’s Canadian RHO Phyto branded dose kinds consisting of topicals, oil drops, sublingual sprays, and pills in series of CBD just and CBD– THC ratios. The items undergo normal pharmaceutical drug advancement, consisting of stability research studies and preclinical analysis where they have actually shown exceptional stability and bioavailability in contrast to fundamental MCT oil formulas. Avicanna continues to advance these formulas through real life proof trials and more preclinical research studies with leading Canadian organizations and clinicians. In addition to its R&D efforts, the Business continues to enhance its present solutions and broaden its pipeline of items to consist of alternative shipment systems. The active pharmaceutical active ingredients for this program are sourced from Avicanna’s bulk owned subsidiary Santa Marta Golden Hemp S.A.S., where the cannabinoids are drawn out from natural and sustainably cultivated plants. The last preparation of these items is finished through Avicanna’s own Great Production Practices (GPP) licensed drug store laboratory in Bogota through its entirely owned subsidiary Avicanna LATAM S.A.S. (” Avicanna LATAM”), which is thought to be the very first of its kind to be licensed for cannabinoid preparations. The education and client assistance programs are likewise handled and run by Avicanna’s medical group to make sure the services satisfy Avicanna’s quality requirements and finish the complete vertical combination.
” At Avicanna, our focus has actually constantly been on clients, and today, with the launch of our medical program, clients in Colombia will have access to restorative options that might add to the control of their comorbidities, enhancing their lifestyle and fixing possible unmet medical requirements entirely. With that, we have actually developed ourselves as a considerable factor to the health system in Colombia, where we mean to likewise present unique pharmaceutical kinds and supply ideal care,” mentioned Dr. Carlos Maldonado, Elder Vice President, Medical Advancement at Avicanna LATAM.
Avicanna’s curriculum consists of healthcare specialist (” HCP”) training plans, instructional modules, accreditations, medical seminar and real-world proof trials. The objective of this curriculum is to add to clinical development through proof generation and to gear up HCPs to supply clients with ideal care. A prompt element of the Business’s curriculum, its approaching occasion entitled Magisterial Solutions: Advances in Cannabinoid Research Study, Item Offering and Client Gain Access To“ on December 10, 2020 at 10am EST, will formally begin the country program.
To sign up for the seminar please go to https://www.bigmarker.com/avicanna-latam-s-a-s/Simposio-de-Avicanna-Colombia-Cannabis-Medicinal
To find out more relating to the Magisterial Preparations call [email protected]
About Avicanna Inc.
Avicanna is a varied and vertically incorporated Canadian biopharmaceutical business concentrated on the research study, advancement, and commercialization of plant-derived cannabinoid-based items for the worldwide customer, medical, and pharmaceutical market sections.
Avicanna is a recognized leader in cannabinoid research study and advancement, which it mostly carries out at its R&D head office in the Johnson & & Johnson Development Centre, JLABS @ Toronto, Canada and in partnership with leading Canadian scholastic and medical organizations. In addition to its establishing pharmaceutical pipeline, Avicanna’s group of specialists have actually established and advertised numerous market leading line of product, consisting of:
- Pura H&W &#x 2122;: a sophisticated and medically evaluated line of CBD customer derma-cosmetic items; and,
- RHO Phyto &#x 2122;: a sophisticated line of medical cannabis items consisting of differing ratios of CBD and THC presently readily available nation-wide throughout Canada in collaboration with Medical Cannabis by Shoppers &#x 2122;, a subsidiary of Shoppers Drug Mart. RHO Phyto is the very first strictly medical formulary of sophisticated “Cannabis 2.0″ items, consisting of oils, sprays, pills, creams, and gels, all 2 established with clinical rigour, made under GMP requirements and supported by pre-clinical information.
With continuous medical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical items, Avicanna’s devotion to looking into the crucial function that cannabinoids play in a progressively larger scope of items has actually been at the core of the Business’s vision given that its beginning. In addition, Avicanna’s dedication to education is shown through its yearly medical seminar, the Avicanna Academy instructional platform, and the My Cannabis Center client program through its subsidiary business.
Avicanna handles its own supply chain consisting of growing and extraction through its 2 majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both situated in Santa Marta, Colombia. Through these sustainable, cost-effective, and commercial scale subsidiaries, Avicanna cultivates, procedures, and advertises a series of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for usage as active pharmaceutical active ingredients. Avicanna’s Avesta Genetica program concentrates on the advancement and optimization of uncommon cultivars for industrial production in addition to feminized seeds for worldwide export. In June 2020, Avicanna made history with a delivery of hemp seeds to the United States of America by finishing the very first export of hemp seeds from Colombia.
SOURCE Avicanna Inc.
To find out more about Avicanna, go to www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by e-mail at [email protected]
Cautionary Note Relating To Forward-Looking Info and Statements
This press release consists of “positive details” within the significance of relevant securities laws. Positive details consisted of in this news release might be recognized by the usage of words such as, “might”, “would”, “might”, “will”, “most likely”, “anticipate”, “prepare for”, “think, “mean”, “strategy”, “projection”, “task”, “price quote”, “outlook” and other comparable expressions, and consists of declarations with resp ec t to the capability of the Business to supply the Colombian population with standardized and sophisticated medical options, the capability of the Business and Avicanna LATAM to produce its line of sophisticated cannabinoid formulas to service private prescriptions released by competent physician, the Business’s capability to set the requirement in Colombia and other Latin America n nations by using items with years of comprehensive research study and advancement made with first-rate quality requirements, the capability of the special formulas to preserve the stability of the cannabinoids throughout treatment, the capability of the Business to source the cannabinoids for the manufacture of the medical cannabis items from Santa Marta Golden Hemp S.A.S., the capability of the item formulas to attend to particular medical conditions, and the capability of Santa Marta Golden Hemp S.A.S. to continue to cultivate cannabis. Positive details is not a warranty of future efficiency and is based upon a variety of price quotes and presumptions of management because of management’s experience and understanding of patterns, present conditions and anticipated advancements, along with other aspects appropriate in the situations, consisting of presumptions in regard of present and future market conditions, the present and future regulative environment; and the schedule of licenses, approvals and authorizations.
Although the Business thinks that the expectations and presumptions on which such positive details is based are sensible, excessive dependence ought to not be put on the positive details since the Business can offer no guarantee that they will show to be right. Real outcomes and advancements might vary materially from those pondered by these declarations. Positive details goes through a range of dangers and unpredictabilities that might trigger real occasions or results to vary materially from those predicted in the positive details. Such dangers and unpredictabilities consist of, however are not restricted to present and future market conditions, consisting of the marketplace cost of the typical shares of the Business, and the danger aspects set out in the Business’s yearly details kind dated April 15, 2020 and last brief kind prospectus outdated November 27, 2020, submitted with the Canadian securities regulators and readily available under the Business’s profile on SEDAR at www.sedar.com
The declarations in this news release are made since the date of this release. The Business disclaims any intent or responsibility to upgrade any positive details, whether as an outcome of brand-new details, future occasions or outcomes or otherwise, besides as needed by relevant securities laws.